US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

VictoryShares US EQ Income Enhanced Volatility Wtd ETF

58.28

-1.0500-1.77%

Volume:36.39K

Turnover:2.16M

Market Cap:690.62M

PE:- -

High:60.69

Open:60.58

Low:57.75

Close:59.33

Loading ...

Overview Company News Filings

Press Release: Atossa Therapeutics Congratulates Board Director Dr. Tessa Cigler and Weill Cornell Medicine on CDC Grant to Enhance Breast Cancer Care

QIAGEN receives positive court decision reaffirming an important QuantiFERON-TB patent

Winner Winner, Chicken Dinner: Tyson Foods Q1 Beat Showcases 'Improved Execution' In Poultry, Says CEO

Budget 2025 likely to talk about cost of living, investments in AI, finance, green transition and fertility: UOB

Former CDC Director Asks Senators to Support RFK Jr.

TNF Pharmaceuticals Launches Study Series Aimed at Preserving Lean Muscle Mass During GLP-1 Weight Loss Treatment

Ocugen, Inc. Announces Investigational New Drug Application in Effect After Review by FDA to Initiate Phase 1 Clinical Trial Evaluating First-in-Class OCU500 Inhaled Vaccine Candidate for COVID-19

Traws Pharma Announces Completion of Phase I Studies with Tivoxavir Marboxil, a Single Dose Oral Investigational Drug for the Treatment and Prevention of H5N1 Bird Flu

Kamada Announces a $25 Million 3-Year Contract for Supply of KAMRAB® and VARIZIG® in Latin America

The world needs Nasodine: Here’s why…

The Market Herald

CDC upgrades its advisory on bird flu. Will Moderna's stock get a boost?

Hospitals Should Test All Influenza Patients for Bird Flu, CDC Says -- Barrons.com

US CDC recommends faster testing for bird flu in hospitalized patients

BRIEF-CDC Issuing Health Advisory To Clinicians Due To Sporadic Human Infections With A(H5N1) Viruses

TNF Pharmaceuticals Announces Positive Clinical Data Supporting Clinical Trial Expansion

Is Oscar Health, Inc. (OSCR) the Best Medical Stock to Buy Under $20?

Why Is Centessa Pharmaceuticals (CNTA) Among the Best Medical Stocks to Buy Under $20?

10 Monday AM Reads

The Big Picture

Is Viatris (VTRS) the Best Medical Stock to Buy Under $20?

Is Elanco Animal Health (ELAN) the Best Medical Stock to Buy Under $20?

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CDC/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CDC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CDC\",,,,,undefined,":{"symbol":"CDC","market":"US","secType":"STK","nameCN":"VictoryShares US EQ Income Enhanced Volatility Wtd ETF","latestPrice":58.28,"timestamp":1744142400000,"preClose":59.33,"halted":0,"volume":36387,"delay":0,"floatShares":11850000,"shares":11850000,"eps":0,"marketStatus":"Pre-Market Trading","change":-1.05,"latestTime":"04-09 06:07:01 EDT","open":60.58,"high":60.6889,"low":57.75,"amount":2159924.09008,"amplitude":0.049535,"askPrice":92.66,"askSize":100,"bidPrice":57,"bidSize":3,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1744205400000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":58.28,"sharesOutstanding":11850000,"nav":59.389527,"aum":703765575,"bidAskSpread":0.00177,"postHourTrading":{"tag":"盘后","latestPrice":58.28,"preClose":58.28,"latestTime":"17:02 EDT","volume":9,"amount":526.05,"timestamp":1744146174764},"volumeRatio":0.3828403893900577,"impliedVol":0.1215,"impliedVolPercentile":0.936},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CDC\",,,,,undefined,":{"symbol":"CDC","floatShares":11850000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.3828403893900577,"shares":11850000,"dividePrice":2.00866,"high":60.6889,"amplitude":0.049535,"preClose":59.33,"low":57.75,"week52Low":56.22,"pbRate":"--","week52High":67.7599,"institutionHeld":0,"latestPrice":58.28,"committee":-0.941748,"eps":0,"divideRate":0.034466,"volume":36387,"delay":0,"ttmEps":0,"open":60.58,"prevYearClose":62.58,"prevWeekClose":60.18,"prevMonthClose":65.72,"prevQuarterClose":65.72,"fiveDayClose":65.41,"twentyDayClose":63.65,"sixtyDayClose":61.46},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CDC\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2509628335","title":"Press Release: Atossa Therapeutics Congratulates Board Director Dr. Tessa Cigler and Weill Cornell Medicine on CDC Grant to Enhance Breast Cancer Care","url":"https://stock-news.laohu8.com/highlight/detail?id=2509628335","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509628335?lang=en_us&edition=fundamental","pubTime":"2025-02-05 21:00","pubTimestamp":1738760400,"startTime":"0","endTime":"0","summary":"Atossa Therapeutics Congratulates Board Director Dr. Tessa Cigler and Weill Cornell Medicine on CDC Grant to Enhance Breast Cancer Care. SEATTLE, Feb. 05, 2025  -- Atossa Therapeutics, Inc.  , a clinical-stage biopharmaceutical company dedicated to the prevention and treatment of breast cancer, extends its sincere congratulations to Dr. Tessa Cigler, esteemed Board Director at Atossa and Associate Professor of Clinical Medicine at Weill Cornell Medicine, and the Weill Cornell Medicine team for being awarded a five-year, $2.3 million grant from the Centers for Disease Control and Prevention . This grant will fund initiatives aimed at improving equitable access to care, quality of life, and survival outcomes for young breast cancer patients across New York City.Dr. Cigler, who serves as co-principal investigator for the initiative, will work alongside Dr. Vered Stearns and a multidisciplinary team at Weill Cornell Medicine to address the unique needs of young breast cancer patients, part","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","CDC","BK4079","BK4548","BK4585","BK4551","ATOS","BK4139","LENZ","Z"],"gpt_icon":0},{"id":"2509494022","title":"QIAGEN receives positive court decision reaffirming an important QuantiFERON-TB patent","url":"https://stock-news.laohu8.com/highlight/detail?id=2509494022","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509494022?lang=en_us&edition=fundamental","pubTime":"2025-02-05 05:05","pubTimestamp":1738703100,"startTime":"0","endTime":"0","summary":"This ruling underscores the strength of QIAGEN’s QuantiFERON intellectual property portfolio and protects the scientific advancements that have made QuantiFERON-TB Gold Plus the global standard for latent TB testing.\"This decision involving an important patent for QuantiFERON reaffirms our ongoing commitment to delivering high-quality, science-driven solutions that improve health for patients around the world. QIAGEN will continue to invest heavily into novel solutions while also vigorously defending its innovations and investments,\" said Thierry Bernard, CEO of QIAGEN.QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics softw","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/qiagen-receives-positive-court-decision-210500944.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1923622614.USD","BK4121","LU2125909247.SGD","QGEN","LU2125909593.SGD","CDC","LU2433249047.HKD"],"gpt_icon":0},{"id":"2508489548","title":"Winner Winner, Chicken Dinner: Tyson Foods Q1 Beat Showcases 'Improved Execution' In Poultry, Says CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2508489548","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508489548?lang=en_us&edition=fundamental","pubTime":"2025-02-04 14:34","pubTimestamp":1738650872,"startTime":"0","endTime":"0","summary":"Tyson Foods reported better-than-expected first-quarter results, driven by robust performance in the chicken sales segment.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/general/market-summary/25/02/43454291/winner-winner-chicken-dinner-tyson-foods-q1-beat-showcases-improved-execution-in-poultry-says-ceo","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4504","MRTYmain","IWO","BK4535","TWM","LU1699723380.USD","TSN","UWM","BK4585","CDC","BK4581","BK4212","TZA","BK4533","BK4534","BK4588","IWM","SRTY","BK4550","TNA","LU1571399168.USD","MNQmain","IWN","RWM"],"gpt_icon":1},{"id":"2508175052","title":"Budget 2025 likely to talk about cost of living, investments in AI, finance, green transition and fertility: UOB","url":"https://stock-news.laohu8.com/highlight/detail?id=2508175052","media":"Felicia Tan","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508175052?lang=en_us&edition=fundamental","pubTime":"2025-02-03 10:01","pubTimestamp":1738548112,"startTime":"0","endTime":"0","summary":"UOB's economist Jester Koh predicts Singapore to have a “modest” fiscal deficit of $2.7 billion or 0.4% of GDP in FY2025.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theedgesingapore.com/news/budget-2025/budget-2025-likely-talk-about-cost-living-investments-ai-finance-green-transition?utm_source=Blog&utm_medium=RSS&utm_campaign=Tiger_Brokers_app_RSS","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"edge_highlight","symbols":["LU0865486749.SGD","SG9999008742.SGD","SG9999004220.SGD","LU0261945553.USD","LU0738912210.USD","SG9999013478.USD","GST","SG9999013460.SGD","U11.SI","LU0251143029.SGD","MOM","SG9999002414.USD","BK6523","LU0572940350.SGD","COE","SG9999002620.SGD","SG9999005177.SGD","LU0264606111.USD","LU0348814723.USD","SG9999000475.SGD","SG9999006266.SGD","LU0414403682.SGD","LU1064131342.USD","SG9999014302.SGD","SG9999000343.SGD","LU1242518931.SGD","SG9999003826.SGD","LU0577902538.SGD","SG9999002679.SGD","LU0588545730.USD","LU2264538146.SGD","LU0251144936.SGD","SGXZ27511609.SGD","SG9999004360.SGD","LU0955669360.SGD","LU0532188223.SGD","SGXZ58947870.SGD","LU1105468828.SGD","BK4204","CDC","SG9999002604.SGD","LU0516423091.SGD","SG9999013486.USD","LU0048573645.USD","PMO","SG9999001127.SGD","LU1988902786.USD","LU0516423174.USD","LU0572939691.SGD","LU0577902371.SGD"],"gpt_icon":0},{"id":"2507652796","title":"Former CDC Director Asks Senators to Support RFK Jr.","url":"https://stock-news.laohu8.com/highlight/detail?id=2507652796","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507652796?lang=en_us&edition=fundamental","pubTime":"2025-01-30 03:19","pubTimestamp":1738178340,"startTime":"0","endTime":"0","summary":"Dr. Robert Redfield, who led the Centers for Disease Control and Prevention during President Trump's first-term administration, asked senators in a letter to confirm Robert F. Kennedy Jr., despite the nominee for secretary of the Department of Health and Human Services attacking Redfield in his 2021 book.Redfield, who supports the \"Make America Healthy Again\" movement, worked with the Trump campaign to help mesh the \"MAGA-MAHA\" alliance between the Trump and Kennedy camps. \"Kennedy is not anti-vaccine,\" Redfield wrote in a letter to senators earlier this week. \"His inquiries prove he's more science-oriented than many of his critics.\". This item is part of a Wall Street Journal live coverage event. The full stream can be found by searching P/WSJL .","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CDC"],"gpt_icon":0},{"id":"2507631281","title":"TNF Pharmaceuticals Launches Study Series Aimed at Preserving Lean Muscle Mass During GLP-1 Weight Loss Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2507631281","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507631281?lang=en_us&edition=fundamental","pubTime":"2025-01-29 22:15","pubTimestamp":1738160100,"startTime":"0","endTime":"0","summary":"Series of studies to observe signals of inflammation and TNF-alpha levels in patients taking GLP-1s including Wegovy or Ozempic. Lean body mass accounts for up to 40% of weight loss from GLP-1 treatments. BALTIMORE, January 29, 2025----TNF Pharmaceuticals, Inc.  , a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, today announced that it has initiated the first in a series of studies to evaluate the impact of its novel oral TNF-alpha  inhibitor drug, isomyosamine, in preserving lean muscle mass during and after GLP-1 treatment for weight loss and chronic weight management.The first study examines TNF-α levels in patients receiving the GLP-1 agonist Wegovy or Ozempic who show signs of increased inflammation associated with sarcopenia, which is the progressive loss of muscle mass. Isomyosamine targets excess pro-inflammatory TNF-alpha, a primary cause of sarcopenia.Isomyosamine is a novel plant alkaloid small mol","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tnf-pharmaceuticals-launches-study-series-141500590.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GLP","CBD","CAGR","BK4144","BK4159","BK4590","TNFA","CDC","ACB","BK4557","BK4113","BK4007"],"gpt_icon":0},{"id":"2506373975","title":"Ocugen, Inc. Announces Investigational New Drug Application in Effect After Review by FDA to Initiate Phase 1 Clinical Trial Evaluating First-in-Class OCU500 Inhaled Vaccine Candidate for COVID-19","url":"https://stock-news.laohu8.com/highlight/detail?id=2506373975","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506373975?lang=en_us&edition=fundamental","pubTime":"2025-01-27 19:30","pubTimestamp":1737977400,"startTime":"0","endTime":"0","summary":"OCU500 will be administered via inhalation and as a nasal sprayCOVID-19 remains a substantial public health threat in the U.S. and around the worldPhase 1 clinical trial is anticipated to start in 2Q ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/27/3015442/0/en/Ocugen-Inc-Announces-Investigational-New-Drug-Application-in-Effect-After-Review-by-FDA-to-Initiate-Phase-1-Clinical-Trial-Evaluating-First-in-Class-OCU500-Inhaled-Vaccine-Candidat.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4563","CDC","BK4551","BK4139","BK4585","BK4535","BK4568","BK4548","BNTX","OCGN"],"gpt_icon":0},{"id":"2505948630","title":"Traws Pharma Announces Completion of Phase I Studies with Tivoxavir Marboxil, a Single Dose Oral Investigational Drug for the Treatment and Prevention of H5N1 Bird Flu","url":"https://stock-news.laohu8.com/highlight/detail?id=2505948630","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505948630?lang=en_us&edition=fundamental","pubTime":"2025-01-23 20:00","pubTimestamp":1737633600,"startTime":"0","endTime":"0","summary":"Phase I completed in healthy volunteers with pharmacokinetic data supporting dosing for both therapeutic and further development for bird flu prevention. NEWTOWN, Pa., Jan. 23, 2025 /PRNewswire/ -- Traws Pharma, Inc.  , a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of respiratory viral diseases, today announced completion of Phase I clinical studies of its investigational one-dose influenza  therapy, tivoxavir marboxil , for the treatment or prevention of H5N1 bird flu.\"We believe that our clinical data in healthy volunteers support accelerated development of tivoxavir marboxil in response to the growing threat of bird flu,\" said Werner Cautreels, PhD, Chief Executive Officer of Traws Pharma.About Tivoxavir MarboxilSeasonal influenza represents an estimated multi-billion antiviral market opportunity, largely driven by global health organizations, practice guidelines and government tenders1, with upside potential from pandemic flu ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/traws-pharma-announces-completion-phase-120000809.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/traws-pharma-announces-completion-phase-120000809.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1169590202.USD","BK4023","LU1169589451.USD","BK4007","TRAW","BK4218","CEN","PK","PD","BK4181","CDC"],"gpt_icon":0},{"id":"2505745766","title":"Kamada Announces a $25 Million 3-Year Contract for Supply of KAMRAB® and VARIZIG® in Latin America","url":"https://stock-news.laohu8.com/highlight/detail?id=2505745766","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505745766?lang=en_us&edition=fundamental","pubTime":"2025-01-22 20:00","pubTimestamp":1737547200,"startTime":"0","endTime":"0","summary":"REHOVOT, Israel and HOBOKEN, N.J., Jan. 22, 2025  -- Kamada Ltd. , a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it was awarded a contract with an international organization for the supply of KAMRAB and VARIZIG in Latin America for 2025-2027. Total expected revenue under the three-year contract for both products is estimated to be approximately $25 million. The expected portion for the calendar year 2025 is incorporated into the Company’s recently announced 2025 revenue guidance.“We are extremely pleased with this significant three-year supply agreement, which we believe validates the global strength of our leading specialty immunoglobulin portfolio and supports our expected multi-year growth outlook,” said Amir London, Kamada’s Chief Executive Officer. “Winning this tender is indicative of the substantial commercial potential of our broad produc","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/kamada-announces-25-million-3-120000485.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0098860793.USD","PEP","LU0234572021.USD","BK4581","IE00BMG7P702.HKD","LU1894683348.USD","IE00B29SXK94.USD","IE00BD4GTT62.SGD","IE00B3T34201.USD","BK4139","LU0320765646.SGD","LU1244550494.USD","LU1929549753.HKD","IE00BMG7P819.SGD","BK4550","KMDA","IE00BMG7P694.USD","ASV","BK4208","BK4504","LU1244550221.USD","BK4177","IE00BMQBXF63.USD","BK4585","LU1244550577.SGD","IE00BZ18W456.USD","D","BK4566","LU1162221912.USD","BK4534","LU1894683264.USD","IE00BMG7P926.USD","IE00BMG7P587.USD","IE00BZ18W340.USD","IE00BD4GTV84.USD","BK4533","IE00B29SXL02.USD","IE00BD4GTW91.USD","BK4588","CDC"],"gpt_icon":0},{"id":"2505234469","title":"The world needs Nasodine: Here’s why…","url":"https://stock-news.laohu8.com/highlight/detail?id=2505234469","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505234469?lang=en_us&edition=fundamental","pubTime":"2025-01-21 03:00","pubTimestamp":1737399600,"startTime":"0","endTime":"0","summary":"Firebrick Pharma’s  Nasodine germicidal nasal spray product – which is based on PVP-iodine, just like Betadine – promises to shake up the ecosystem of products treating the common cold.Company Executive Chair Dr Peter Molloy, who originally developed Betadine Sore Throat Gargle in Australia, has previously outlined to HotCopper why Nasodine is superior to other cold treatments.The compound is a germicide and not a decongestant or cough suppressant, meaning that unlike other cold treatment drugs, Nasodine actually targets the cause of the common cold.Nasodine is ultimately a disease prevention and treatment product, standing out from the rest.The last time Molloy spoke to HotCopper, we looked at how the recent COVID-19 debacle had heightened awareness, for better or worse, of global disease spreading broadly .We’d suggested we wouldn’t be far away from the next pandemic risk event – and that’s exactly what we’re looking at now, though it’s important to note the World Health Organisation","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/the-world-needs-nasodine-heres-why-2025-01-21/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["CDC","BK7096","FRE.AU"],"gpt_icon":0},{"id":"2504571944","title":"CDC upgrades its advisory on bird flu. Will Moderna's stock get a boost?","url":"https://stock-news.laohu8.com/highlight/detail?id=2504571944","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504571944?lang=en_us&edition=fundamental","pubTime":"2025-01-17 03:45","pubTimestamp":1737056700,"startTime":"0","endTime":"0","summary":"Agency is now calling for all patients hospitalized with flu to be tested for H5 avian flu. Patients hospitalized with flu should be tested for H5N1 bird flu within 24 hours, the Centers for Disease Control and Prevention said Thursday, upgrading its recent recommendation.Before now, the agency was advising that patients hospitalized with flu who had been in contact with animals should be tested - but it's now extending that advice to all flu patients.The latest advisory comes a week after the first human bird-flu death was announced - an individual in Louisiana who had been hospitalized with a severe infection.\"While tragic, a death from H5N1 bird flu in the United States is not unexpected because of the known potential for infection with these viruses to cause severe illness and death,\" the CDC said at the time.A number of drug companies are working to develop a vaccine, led by Moderna Inc., which won a $176 million award from the Biomedical Advanced Research and Development Authorit","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":"c9235e7c37f9a06f386a73723c409b61","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRNA","CDC"],"gpt_icon":1},{"id":"2504194508","title":"Hospitals Should Test All Influenza Patients for Bird Flu, CDC Says -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2504194508","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504194508?lang=en_us&edition=fundamental","pubTime":"2025-01-17 02:23","pubTimestamp":1737051780,"startTime":"0","endTime":"0","summary":"Any patient hospitalized with influenza should be quickly checked for H5N1 bird flu, the Centers for Disease Control and Prevention said Thursday, as the federal government continues to ramp up its preparations for a potential pandemic.The new policy comes a week after a 5-year-old child in San Francisco tested positive for bird flu, despite no known exposure to infected animals. The child was not hospitalized and has recovered.The H5N1 bird flu virus has been spreading widely in U.S. dairy cattle for nearly a year, and has been decimating poultry farms since 2022. The CDC has confirmed 67 human cases since last year in the U.S., one of them fatal. Experts have long feared that H5N1 has the potential to set off a human pandemic.The CDC had previously said that flu patients who had been in contact with sick animals should be tested immediately for H5N1. The new guidance extends that recommendation to all hospitalized influenza patients.Now, the CDC is telling hospitals that they should ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"c9235e7c37f9a06f386a73723c409b61","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CDC"],"gpt_icon":0},{"id":"2504545914","title":"US CDC recommends faster testing for bird flu in hospitalized patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2504545914","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504545914?lang=en_us&edition=fundamental","pubTime":"2025-01-17 00:13","pubTimestamp":1737044001,"startTime":"0","endTime":"0","summary":"Jan 16  - The U.S. Centers for Disease Control and Prevention on Thursday urged clinicians and laboratories to test for the variant of influenza A virus in patients ideally within 24 hours of hospitalization, as part of its efforts to tackle the ongoing sporadic human infections with bird flu. ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CDC"],"gpt_icon":0},{"id":"2504001911","title":"BRIEF-CDC Issuing Health Advisory To Clinicians Due To Sporadic Human Infections With A(H5N1) Viruses","url":"https://stock-news.laohu8.com/highlight/detail?id=2504001911","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504001911?lang=en_us&edition=fundamental","pubTime":"2025-01-17 00:07","pubTimestamp":1737043640,"startTime":"0","endTime":"0","summary":"Jan 16  - CDC:   * CDC: ISSUING HEALTH ADVISORY TO CLINICIANS DUE TO SPORADIC HUMAN INFECTIONS WITH A VIRUSES AMID HIGH LEVELS OF SEASONAL INFLUENZA ACTIVITY   * CDC: RECOMMENDING SHORTENED TIMELINE FOR SUBTYPING ALL INFLUENZA A SPECIMENS AMONG HOSPITALIZED PATIENTS   * CDC: RECOMMENDING INCREASING EFFORTS AT CLINICAL LABORATORIES TO IDENTIFY NON-SEASONAL INFLUENZA   * CDC: STILL CONSIDERS RISK FROM AVIAN INFLUENZA A VIRUSES TO PUBLIC TO BE LOW BUT IS CLOSELY MONITORING SITUATION","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CDC"],"gpt_icon":0},{"id":"2503164293","title":"TNF Pharmaceuticals Announces Positive Clinical Data Supporting Clinical Trial Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2503164293","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503164293?lang=en_us&edition=fundamental","pubTime":"2025-01-15 22:15","pubTimestamp":1736950500,"startTime":"0","endTime":"0","summary":"Set to begin larger Phase 2b study in sarcopenia and new trial in GLP-1-induced sarcopenia and frailty. Transformative potential for novel TNF-alpha inhibitor drug:Estimated $40 billion TNF inhibitor market and $50 billion GLP-1 agonist market. BALTIMORE, January 15, 2025----TNF Pharmaceuticals, Inc.  , a clinical stage biopharmaceutical company committed to developing novel oral therapies for autoimmune and inflammatory conditions, today announced that it has achieved a key safety data milestone supporting expanded and longer-term clinical studies of its novel TNF-alpha  inhibitor drug, isomyosamine, in multiple indications.\"Positive data from this milestone study confirms isomyosamine’s historically strong safety profile and enables us to extend the duration of future clinical trials,\" said Mitchell Glass, M.D., President and Chief Medical Officer of TNFA. \"We believe we are fully equipped to advance our comprehensive isomyosamine platform in a longer-term clinical trial in sarcopeni","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tnf-pharmaceuticals-announces-positive-clinical-141500016.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4159","TNFA","CBD","CDC","ACB","BK4113","BK4007","BK4557","CAGR"],"gpt_icon":0},{"id":"2503520542","title":"Is Oscar Health, Inc. (OSCR) the Best Medical Stock to Buy Under $20?","url":"https://stock-news.laohu8.com/highlight/detail?id=2503520542","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503520542?lang=en_us&edition=fundamental","pubTime":"2025-01-14 20:53","pubTimestamp":1736859200,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the 12 Best Medical Stocks To Buy Under $20. In this article, we are going to take a look at where Oscar Health, Inc.  stands against the other best medical stocks under $20.The medical industry plays a crucial role in ensuring the health and safety of populations. Driven by advancements in medical technology and an aging population, the medical and healthcare industry is expected to grow significantly in the coming years.READ ALSO: 10 Best Low Priced Technology Stocks To Buy Now and 8 Undervalued Insurance Stocks To Invest In.According to Deloitte’s 2024 Global Healthcare Sector Outlook, the use of technologies like artificial intelligence  is rising in the healthcare sector. Healthcare providers and technology companies are introducing various kinds of AI tools that can help improve clinical outcomes. These technological advancements can streamline various administrative tasks while also enhancing the quality of care provided to patients.However, Kenned","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/oscar-health-inc-oscr-best-125320622.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CDC","LU2346227817.USD","BK4551","OSCR","BK4588","BK4585","CAGR","CMS","LU1894683348.USD","BK4208","LU1894683264.USD","LU2637428348.USD","BK4159","BK4162"],"gpt_icon":0},{"id":"2503589612","title":"Why Is Centessa Pharmaceuticals (CNTA) Among the Best Medical Stocks to Buy Under $20?","url":"https://stock-news.laohu8.com/highlight/detail?id=2503589612","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503589612?lang=en_us&edition=fundamental","pubTime":"2025-01-13 22:51","pubTimestamp":1736779875,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the Best Medical Stocks To Buy Under $20. In this article, we are going to take a look at where Centessa Pharmaceuticals plc  stands against the other best medical stocks under $20.The medical industry plays a crucial role in ensuring the health and safety of populations. Driven by advancements in medical technology and an aging population, the medical and healthcare industry is expected to grow significantly in the coming years.READ ALSO: 10 Best Low Priced Technology Stocks To Buy Now and 8 Undervalued Insurance Stocks To Invest In.According to Deloitte’s 2024 Global Healthcare Sector Outlook, the use of technologies like artificial intelligence  is rising in the healthcare sector. Healthcare providers and technology companies are introducing various kinds of AI tools that can help improve clinical outcomes. These technological advancements can streamline various administrative tasks while also enhancing the quality of care provided to patients.However,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-centessa-pharmaceuticals-cnta-among-145115603.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","LU1894683264.USD","BK4563","BK4539","CMS","BK4139","TSYW.SI","BK4535","NQmain","USAW.SI","TQQQ","QLD","CNTA","LU2346227817.USD","PSQ","USJW.SI","QID","LU2637428348.USD","BK4208","QQQ","BK4510","IH","SQQQ","CDC","LU1894683348.USD","NVIW.SI","MNQmain","BK4085",".IXIC","BK4588"],"gpt_icon":0},{"id":"2503052983","title":"10 Monday AM Reads","url":"https://stock-news.laohu8.com/highlight/detail?id=2503052983","media":"The Big Picture","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503052983?lang=en_us&edition=fundamental","pubTime":"2025-01-13 19:30","pubTimestamp":1736767821,"startTime":"0","endTime":"0","summary":"Stocks Are More Expensive Than They Used to Be: Companies are better today and deserve the premium multiple. But its reasonable to “Expect lower returns.”How Analyst Job Cuts on Wall Street Are Reshaping Equity Research: Forces like regulation, passive investing and AI have all conspired to squeeze equity research in ways few could have imagined. Countless “sell-side” analysts have had to reinvent themselves as a result. . How to Make the Most of the New ‘Super Catch-Ups’ for 401s: Savers in their early 60s can sock away nearly $35,000 in their 401 account for retirement in 2025, thanks to the new “super catch-up” rules. The higher contribution limits aren’t a slam dunk for everyone, though, and you may need to make adjustments to other retirement accounts to maximize your savings. . The Lamentation of David Einhorn: Greenlight Capital’s David Einhorn has long been talking about how markets are “fundamentally broken”, but he reckons things will get much worse before they get better — i","market":"us","thumbnail":"https://ritholtz.com/wp-content/uploads/2026/12/stomachbug.png","type":0,"news_type":0,"thumbnails":["https://ritholtz.com/wp-content/uploads/2026/12/stomachbug.png"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://ritholtz.com/2025/01/10-monday-am-reads-418/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"ritholtz_highlight","symbols":["LU1032466523.USD","LU2347655156.SGD","LU2452424414.USD","IE0034235188.USD","CDC","IE00BK4W5M84.HKD","LU2133065610.SGD","GOOGL","LU1236620750.USD","LU0345770308.USD","IE00BYQQ9H92.USD","FT","LU2087621335.USD","LU0882574139.USD","LU2098885051.SGD","LU0251131958.USD","SG9999004303.SGD","LU0683600562.USD","SG9999018865.SGD","LU0314104364.USD","LU2242649171.HKD","IE00BMPRXR70.SGD","LU2095319765.USD","LU1670711123.USD","MSFT","LU0187121727.USD","LU0823421333.USD","LU1989764748.USD","LU2271345857.HKD","LU0267386448.USD","LU2028103732.USD","LU2125154935.USD","BK4581","LU0757359368.USD","LU0314106906.USD","LU0861579265.USD","LU0345770993.USD","IE00BN8TJ469.HKD","IE00B4JS1V06.HKD","LU1989764664.SGD","LU2242650005.HKD","LU1059921491.USD","LU2250418816.HKD","IE00B3S45H60.SGD","BK4144","LU2764263203.CNY","LU2756315318.SGD","LU0080751232.USD","AM","LU1267930490.SGD"],"gpt_icon":1},{"id":"2502360976","title":"Is Viatris (VTRS) the Best Medical Stock to Buy Under $20?","url":"https://stock-news.laohu8.com/highlight/detail?id=2502360976","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502360976?lang=en_us&edition=fundamental","pubTime":"2025-01-12 22:42","pubTimestamp":1736692957,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the Best Medical Stocks To Buy Under $20. In this article, we are going to take a look at where Viatris Inc.  stands against the other best medical stocks under $20.The medical industry plays a crucial role in ensuring the health and safety of populations. Driven by advancements in medical technology and an aging population, the medical and healthcare industry is expected to grow significantly in the coming years.READ ALSO: 10 Best Low Priced Technology Stocks To Buy Now and 8 Undervalued Insurance Stocks To Invest In.According to Deloitte’s 2024 Global Healthcare Sector Outlook, the use of technologies like artificial intelligence  is rising in the healthcare sector. Healthcare providers and technology companies are introducing various kinds of AI tools that can help improve clinical outcomes. These technological advancements can streamline various administrative tasks while also enhancing the quality of care provided to patients.However, Kennedy is know","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/viatris-vtrs-best-medical-stock-144237125.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4208","QID","SQQQ","BK4583","LU1894683264.USD","BK4585","MNQmain","TQQQ","BK4588","LU2087621335.USD","QLD","VTRS","CDC","NVIW.SI","PSQ","TSYW.SI","BK4007","USJW.SI","CMS","LU2637428348.USD","NQmain",".IXIC","LU1839511570.USD","USAW.SI","LU2346227817.USD","LU1894683348.USD"],"gpt_icon":1},{"id":"2502362069","title":"Is Elanco Animal Health (ELAN) the Best Medical Stock to Buy Under $20?","url":"https://stock-news.laohu8.com/highlight/detail?id=2502362069","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502362069?lang=en_us&edition=fundamental","pubTime":"2025-01-12 22:38","pubTimestamp":1736692708,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the Best Medical Stocks To Buy Under $20. In this article, we are going to take a look at where Elanco Animal Health Incorporated  stands against the other best medical stocks under $20.The medical industry plays a crucial role in ensuring the health and safety of populations. Driven by advancements in medical technology and an aging population, the medical and healthcare industry is expected to grow significantly in the coming years.READ ALSO: 10 Best Low Priced Technology Stocks To Buy Now and 8 Undervalued Insurance Stocks To Invest In.According to Deloitte’s 2024 Global Healthcare Sector Outlook, the use of technologies like artificial intelligence  is rising in the healthcare sector. Healthcare providers and technology companies are introducing various kinds of AI tools that can help improve clinical outcomes. These technological advancements can streamline various administrative tasks while also enhancing the quality of care provided to patients.How","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/elanco-animal-health-elan-best-143828284.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CMS","LU1894683264.USD","BK4585","CDC","BK4561","BK4208","LU2637428348.USD","LU2346227817.USD","BK4007","BK4588","ELAN","LU1894683348.USD"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":4,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CDC\",params:#limit:5,,,undefined,":[{"date":"2025-03-10","symbol":"CDC","amount":0.20589,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-10","defaultRemindTime":1741613400000,"name":"VictoryShares US EQ Income Enhanced Volatility Wtd ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-11","payableDate":"2025-03-10","currency":"USD","dateTimestamp":1741579200000,"payDate":"2025-03-11"},{"date":"2025-02-07","symbol":"CDC","amount":0.133071,"announcedDate":"2025-02-06","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-02-07","defaultRemindTime":1738938600000,"name":"VictoryShares US EQ Income Enhanced Volatility Wtd ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-02-10","payableDate":"2025-02-07","currency":"USD","dateTimestamp":1738904400000,"payDate":"2025-02-10"},{"date":"2025-01-08","symbol":"CDC","amount":0.007166,"announcedDate":"2025-01-07","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-01-08","defaultRemindTime":1736346600000,"name":"VictoryShares US EQ Income Enhanced Volatility Wtd ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-01-09","payableDate":"2025-01-08","currency":"USD","dateTimestamp":1736312400000,"payDate":"2025-01-09"},{"date":"2024-12-12","symbol":"CDC","amount":0.414202,"announcedDate":"2024-12-11","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-12","defaultRemindTime":1734013800000,"name":"VictoryShares US EQ Income Enhanced Volatility Wtd ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-13","payableDate":"2024-12-12","currency":"USD","dateTimestamp":1733979600000,"payDate":"2024-12-13"},{"date":"2024-11-07","symbol":"CDC","amount":0.120986,"announcedDate":"2024-11-06","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-11-07","defaultRemindTime":1730989800000,"name":"VictoryShares US EQ Income Enhanced Volatility Wtd ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-11-08","payableDate":"2024-11-07","currency":"USD","dateTimestamp":1730955600000,"payDate":"2024-11-08"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CDC\",market:\"US\",,,undefined,":[{"executeDate":"2015-04-21","recordDate":"2015-04-23","paymentDate":"2015-04-24","value":0.0278085,"currency":"USD"},{"executeDate":"2015-05-19","recordDate":"2015-05-21","paymentDate":"2015-05-22","value":0.1054201,"currency":"USD"},{"executeDate":"2015-06-16","recordDate":"2015-06-18","paymentDate":"2015-06-19","value":0.1094172,"currency":"USD"},{"executeDate":"2015-07-21","recordDate":"2015-07-23","paymentDate":"2015-07-24","value":0.0106339,"currency":"USD"},{"executeDate":"2015-08-18","recordDate":"2015-08-20","paymentDate":"2015-08-21","value":0.1070379,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CDC\",market:\"US\",delay:false,,,undefined,":{}}}